US 12,134,632 B2
On-column viral inactivation methods
Glen Bolton, Boston, MA (US); and Keith Selvitelli, Sutton, MA (US)
Assigned to BIOVERATIV THERAPEUTICS INC., Waltham, MA (US)
Filed by BIOVERATIV THERAPEUTICS INC., Waltham, MA (US)
Filed on Jan. 12, 2023, as Appl. No. 18/153,669.
Application 18/153,669 is a continuation of application No. 16/793,676, filed on Feb. 18, 2020, granted, now 11,578,098.
Application 16/793,676 is a continuation of application No. 15/024,988, granted, now 10,611,794, issued on Apr. 7, 2020, previously published as PCT/US2014/057524, filed on Sep. 25, 2014.
Claims priority of provisional application 62/028,657, filed on Jul. 24, 2014.
Claims priority of provisional application 61/882,488, filed on Sep. 25, 2013.
Prior Publication US 2023/0331774 A1, Oct. 19, 2023
Int. Cl. A61L 2/00 (2006.01); A61K 35/14 (2015.01); A61K 35/16 (2015.01); A61K 38/00 (2006.01); C07K 1/16 (2006.01); C07K 1/22 (2006.01); C07K 14/755 (2006.01); C07K 16/06 (2006.01)
CPC C07K 1/22 (2013.01) [A61L 2/0088 (2013.01); C07K 1/165 (2013.01); C07K 14/755 (2013.01); C07K 16/065 (2013.01); A61L 2202/21 (2013.01); C07K 2319/30 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of inactivating virus present during production of a polypeptide of interest, comprising:
(a) binding the polypeptide to a chromatography matrix,
(b) performing a virus inactivation step by washing the polypeptide-bound chromatography matrix with a wash solution at a pH of lower than about 4.0,
(c) eluting the polypeptide from the chromatography matrix with a low-salt elution solution, wherein the wash solution comprises a sufficient concentration of salt to substantially reduce elution of the polypeptide during the virus inactivation step.